Targeting
CNS Conditions
utilizing genomic biomarkers to develop therapeutics for people of all ages.
%20copy%2018.png)
Anavex Life Sciences Provides Business Update & Reports Fiscal 2022 Second Quarter Financial Results on May 10, 2022.
Recording of webcast is available by clicking on webcast button below.
Welcome to Anavex Life Sciences Corp. Our SIGMACEPTOR™ Discovery Platform produces therapeutic candidates designed to activate SIGMAR1, a novel pathway designed to target chronic central nervous system (CNS) conditions with genomic precision.
Person-focused Dedication
Our product portfolio platform is inspired by the lived experiences of the people living with neurodegenerative and neurodevelopmental disorders and the strength and dedication of carers.
Therapeutic Candidates
Recent research findings suggest that the small molecule therapeutic candidates produced by our proprietary portfolio platform establishes novel modes of action aimed at a variety of CNS disorders like Alzheimer's disease, Parkinson's disease, Rett syndrome and others.
Understanding SIGMAR1
Our proprietary SIGMACEPTOR™ discovery platform produces therapeutic candidates that lead to the modulation of SIGMAR1. Data suggests that activation of SIGMAR1 results in the restoration of complete housekeeping function within the body and is pivotal to neural cell homeostasis and neuroplasticity.
Corporate Presentation
Our corporate presentation contains forward-looking statements. Potential investors should refer to the risk factors in our reports filed on Edgar.
News & Events
A therapeutic approach for all ages
The SIGMACEPTOR™ Discovery Platform is designed to produce therapeutic candidates for people of all ages. From neurodevelopment to neurodegenerative conditions, our SIGMAR1 portfolio platform enables therapeutic discovery utilizing the body's own defense mechanism to restore function.
“Assisting the body in re-establishing homeostasis could very well be a key therapeutic step to solving several life-altering CNS conditions.”
Christopher U. Missling PhD, MS, MBA
President and CEO